Cyclerion Therapeutics (KRSA) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases involving the central nervous system, cardiovascular system, kidneys and other organs. The company’s research centered on soluble guanylate cyclase stimulators, a class of compounds designed to influence cellular signaling pathways associated with blood flow, inflammation and tissue function.

Cyclerion’s development portfolio historically included IW-6463, an investigational central nervous system therapy, as well as olinciguat and praliciguat, which were studied for potential applications in conditions including neurodegenerative disease, sickle cell disease and diabetic kidney disease. The company was founded in 2019 as a spinout from Ironwood Pharmaceuticals and was headquartered in Cambridge, Massachusetts. Peter Hecht, Ph.D., served as its chief executive officer during a significant portion of its operations.

Public information identifies Cyclerion’s historical Nasdaq trading symbol as CYCN rather than KRSA, and the company’s corporate status and operations may have changed since its period as an independent biotechnology business.

Key Stats

• Today's Range: $32.61 to $32.70
• 50-Day Range: N/A
• 52-Week Range: $7.19 to $59.36
• Volume: 893 shs
• Average Volume: 289,203 shs
• Market Capitalization: $21.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $53.00
• Consensus Rating: Moderate Buy

Cyclerion Therapeutics Stock Analysis - MarketRank™

Cyclerion Therapeutics scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cyclerion Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Cyclerion Therapeutics has a consensus price target of $53.00, representing about 67.7% upside from its current price of $31.60.

Amount of Analyst Coverage

Cyclerion Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cyclerion Therapeutics are expected to decrease in the coming year, from ($2.11) to ($3.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclerion Therapeutics is -2.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclerion Therapeutics has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.63% of the float of Cyclerion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclerion Therapeutics has a short interest ratio ("days to cover") of 0.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclerion Therapeutics has recently increased by 160.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclerion Therapeutics does not currently pay a dividend.

Dividend Growth

Cyclerion Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.21

News Sentiment

Cyclerion Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Cyclerion Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for KRSA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:KRSA
• Previous Symbol: NASDAQ:CYCN
• CIK: 1755237
• Web: www.korsana.com
• Phone: (617) 621-7722
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cyclerion Therapeutics: $53.00
• High Price Target: $70.00
• Low Price Target: $43.00
• Potential Upside/Downside: +63.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.53 million
• Net Margins: N/A
• Pretax Margin: -353.00%
• Return on Equity: -87.96%
• Return on Assets: -74.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.82
• Quick Ratio: 0.82

Sales & Book Value

• Annual Sales: $2.07 million
• Price / Sales: 10.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.20 per share
• Price / Book: 2.01

Miscellaneous

• Outstanding Shares: 670,000
• Free Float: 440,000
• Market Cap: $21.78 million
• Optionable: N/A
• Beta: 1.72